June 18, 2020

HK inno.N Announces IND Approval for Tegoprazan for Treatment of Gastroesophageal Reflux Disease in USA

HK inno.N Corporation (Joint representative directors: Seok-Hee Kang and Sang-Hyun Yoon, headquartered in Seoul, Korea; hereinafter called "HK inno.N") announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for tegoprazan (RQ-00000004/CJ-12420/K-CAB®, hereinafter called "tegoprazan") for the treatment of gastroesophageal reflux disease.

RaQualia completed the Phase I clinical trial of tegoprazan successfully in the U.S. in August 2010. HK inno.N plans to conduct an alternative Phase I clinical trial to facilitate the development in the U.S. by using tegoprazan tablets that have been already marketed in Korea.

In November 2019, RaQualia entered into an agreement with CJ HealthCare Corporation (currently HK inno.N) to expand its global partnership and grant a license for tegoprazan in North America and Europe. RaQualia is eligible to receive milestone payments as the development of tegoprazan progresses, as well as royalties on the sales of tegoprazan.

For further details, please refer to the HK inno.N official website at: http://www.inno-n.com/company/publicity_center/report_data/list.asp